Alumis Plans Late Stage Lupus Study
Alumis will advance its experimental lupus drug into late stage trials despite missing the main goal in a mid stage study. Shares slumped over fifty five percent in premarket trading following the disappointing results.
Xurve View
Insights:
Xurve View
ALUMIS INC will advance its experimental lupus drug into late-stage testing after a mid-stage trial missed its main goal, sending shares down 55% in Tuesday premarket trading. The trial failure marks a setback in a therapeutic area historically plagued by high clinical attrition rates. Over 200,000 patients in the United States suffer from systemic lupus erythematosus, according to federal health data.
